Monopar Therapeutics Files 8-K: Material Agreement

Ticker: MNPR · Form: 8-K · Filed: 2024-10-30T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, filing

Related Tickers: MNPR

TL;DR

Monopar (MNPR) signed a big deal, filing an 8-K. Details to come.

AI Summary

Monopar Therapeutics Inc. announced on October 28, 2024, that it entered into a material definitive agreement. The company also disclosed information related to Regulation FD and filed financial statements and exhibits as part of this 8-K filing. Specific details of the agreement and financial statements were not provided in the excerpt.

Why It Matters

This filing indicates a significant development for Monopar Therapeutics, potentially involving a new partnership, acquisition, or other material contract that could impact its business operations and future prospects.

Risk Assessment

Risk Level: medium — The filing itself is routine, but the 'material definitive agreement' could represent significant opportunities or risks depending on its nature, which is not detailed here.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Monopar Therapeutics?

The provided excerpt does not specify the details of the material definitive agreement.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on October 28, 2024.

What is Monopar Therapeutics' principal executive office address?

Monopar Therapeutics' principal executive office is located at 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091.

What items are covered in this 8-K filing?

This 8-K filing covers Entry into a Material Definitive Agreement, Regulation FD Disclosure, and Financial Statements and Exhibits.

What is Monopar Therapeutics' state of incorporation?

Monopar Therapeutics is incorporated in Delaware.

From the Filing

0001437749-24-032612.txt : 20241030 0001437749-24-032612.hdr.sgml : 20241030 20241030160520 ACCESSION NUMBER: 0001437749-24-032612 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20241028 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241410256 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20241029_8k.htm FORM 8-K mnpr20241029_8k.htm false 0001645469 0001645469 2024-10-28 2024-10-28     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 28, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒           Item 1.01.             Entry into a Material Definitive Agreement.   On October 28, 2024, Monopar Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a placement agent agreement (the “ Placement Agent Agreement ”) with Rodman & Renshaw LLC (the “ Placement Agent ”) in connection with the offer and sale to investors of up to 1,181,540 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share, at an offering pric

View on Read The Filing